Goldman Sachs Group Inc. Increases Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Goldman Sachs Group Inc. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 831,911 shares of the company’s stock after buying an additional 119,969 shares during the quarter. Goldman Sachs Group Inc. owned about 1.04% of IDEXX Laboratories worth $562,813,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IDXX. Beacon Investment Advisory Services Inc. grew its stake in shares of IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after purchasing an additional 6,710 shares during the period. Nordea Investment Management AB increased its stake in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after purchasing an additional 8,845 shares in the last quarter. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth $1,966,000. NEOS Investment Management LLC raised its stake in IDEXX Laboratories by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock valued at $19,199,000 after purchasing an additional 13,599 shares during the last quarter. Finally, Diversified Trust Co. raised its position in shares of IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after buying an additional 2,901 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Piper Sandler dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Up 0.7%

Shares of NASDAQ IDXX opened at $564.74 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market cap of $44.55 billion, a price-to-earnings ratio of 41.59, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The stock’s 50 day simple moving average is $563.32 and its 200 day simple moving average is $632.63.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.